Whether Regorafenib Is Becoming More Tolerable For mCRC Patients

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Whether Regorafenib Is Becoming More Tolerable For mCRC Patients. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com